Quantum BioPharma announces the following corporate updates: On August 12, 2025, the board of directors of the Company authorized the settlement of outstanding debt with one creditor in the amount of $26,812.50 USD by converting the debt into 1,102 Class B Shares at a deemed price of $24.33 USD per Class B Share. On August 15, 2025, the Board authorized and approved the grant of restricted share units pursuant to the Equity Incentive Plan. The Company granted 800 RSUs each to Peter Stys and Jack Antel. Effective August 15, 2025, the Company terminated the Board Advisor Agreement dated July 1, 2025, with Kevin Malone, and as a result, Malone is no longer serving as an Advisor to the Company’s Board of Directors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Seeks Shareholder Approval for Private Placement
- Quantum BioPharma Advances Lucid-MS for Phase 2 MS Trial
- Quantum signs agreement with CDMO to manufacture oral Lucid-21-302
- Quantum BioPharma Reports Promising PET Tracer Results for MS
- Quantum BioPharma announces results from study on PET tracer